Skip to main content
. 2020 Sep 17;11(9):769. doi: 10.1038/s41419-020-02944-6

Fig. 2. Induction of apoptosis by BDA-366 in DLBCL.

Fig. 2

a Concentration-response curves of the DLBCL cell lines SU-DHL-4, KARPAS-422, SU-DHL-6, Ri-1, TOLEDO, OCI-LY-1, OCI-LY-18, and PFEIFFER treated with increasing concentrations of BDA-366. After 24 h the level of apoptosis was measured using flow cytometeric analysis in Annexin V-FITC/7-AAD stained cells. Data represented here are averages ± SEM of at least three independent experiment (N > 3). b Quantification of the expression levels of Bcl-2 in several cell lines (right) normalized to SU-DHL-4 (left). Correlation plot of the LD50 values for BDA-366-induced cell death and different Bcl-2-family protein expression levels in distinct cell lines obtained via linear regression analysis (right). Data are presented as average ± SD of three independent experiments (N = 3). c Concentration-response curves of two DLBCL cell lines and two murine thymocytes respectively: HT, HT overexpressing Bcl-2 (HT Bcl-2), Wehi7.2 overexpressing (Wehi7.2 Bcl-2) and Wehi7.2. Cell lines were treated with increasing concentrations of BDA-366. After 24 h the level of apoptosis was measured using flow cytometric analysis in Annexin V-FITC/7-AAD stained cells. Data represented here are averages ± SEM of at least three independent experiment (N > 3). d Overexpression of Bcl-2 in primary human CLL cells by Bcl-2 mRNA transfection increases resistance to BDA-366 and venetoclax. Primary human CLL cells (n = 6) were transfected with control (Ctrl) or Bcl-2 mRNA, left in culture for 3 h to achieve maximal Bcl-2-protein expression, and were then exposed to BDA-366 (1 μM) or venetoclax (4 nM). The viability of the leukemic cells was determined after 20 h by Annexin V/PI staining. Statistical analysis was done with the paired t test for the comparison of the control and the venetoclax-treated cells, whereas because of non-normal distribution the Wilcoxon Signed Rank test was applied for the comparison of the BDA-366-treated cells.